GC203 wani sabon maganin TIL ne wanda ba shi da ƙwayoyin cuta wanda aka gyara ta hanyar kwayar halitta, wanda aka haɓaka ta amfani da dandamalin faɗaɗa ƙwayoyin halitta na DeepTIL® na Juncell Therapeutics da dandamalin gyaran ƙwayoyin halitta na NovaGMP®. DeepTIL® yana ba TILs damar yin ƙarfi sosai har ba za a buƙaci haɗin IL-2 ba bayan jiko, kuma ƙarfin magani kafin a fara magani na iya zama ƙasa. NovaGMP® yana gyara ƙwayoyin T tare da babban inganci wanda aka kwatanta da vector na Lentiviral ta hanyar tattalin arziki. An ƙera GC203 tare da interleukin-7 mai ɗaure da membrane, wanda zai iya kula da ƙarfin ƙwayoyin ƙwaƙwalwar T, kunna ƙwayoyin rigakafi na ciki da kuma guje wa guba na tsarin.
Masu bincike sun gwada GC203 akan marasa lafiya da aka gano suna da cutar kansar mahaifa mai sake dawowa, ba tare da haɗakar shan IL-2 ko kuma yawan lymphostasis mai tsanani ba. Manufar binciken ita ce a tantance aminci da ingancin wannan maganin. Jimillar marasa lafiya 20 ne aka yi wa rajista tsakanin 09/2021 da 01/2024 a cikin gwajin da aka yi a tsakiya ɗaya, wanda aka kimanta marasa lafiya 18. Marasa lafiya da aka kimanta suna da ECOG PS na 1 (55.6%) ko 2 (44.4%) kuma sun sami matsakaicin jiyya 5 na tsarin da aka yi a baya (tsakanin: 2-11). Marasa lafiya 9 (50%) suna da raunuka 3 ko fiye da ƙari. Matsakaicin girman raunukan da aka yi niyya shine 57 (tsakanin: 13-146) mm.
GC203 ya nuna sakamako mai kyau ga marasa lafiya da ke fama da ciwon daji na ovarian da ke sake dawowa ko kuma ya fara yaduwa. An inganta yanayin tsaro sosai idan aka kwatanta da magungunan TIL na gargajiya, godiya ga ƙarancin ƙarfi kafin a yi musu magani da kuma kawar da haɗin IL-2. Yawancin Abubuwan da suka Faru (AEs) aji 1 ko aji 2 ne kuma ana iya rage su ko warkar da su ta hanyar maganin alamun. Babu wani abin da ya faru a aji 5. Kafin ranar ƙarshe ta 01/2024, ƙimar Amsar Manufofi (ORR) da mai binciken ya tantance shine 33.3% (95% CI: 16.3 – 56.3), gami da 11.1% Cikakken Amsa (CR). Matsakaicin Kula da Cututtuka (DCR) shine 83.3% (95% CI, 60.8 – 94.2). Kuma ƙimar Jimlar Rayuwa (OS) ta watanni 12 shine 68.8% (95% CI: 49.3 – 95.9). Matsakaicin OS bai cika ba yayin yanke bayanai.
A shekarar 2023, an kwantar da Ms. H a asibiti a shekarar 2023 saboda matsalar cinyar mahaifa.da ciwon kuguBayan an yi mata gwaji, an gano cewa ƙwayoyin lymph da yawa sun ƙaru a cikin retroperitoneum, maƙogwaro, da sauran wurare, wanda hakan ya tabbatar da cewa tana da cutar kansar mahaifa mai tsanani. Don haka Ms. H ta yi amfani da chemotherapy, tiyata, immunotherapy, da sauransu, amma tasirin bai yi kyau ba, kuma ciwon ya sake dawowa.
Saboda haka, Ms. H ta shiga cikin gwajin asibiti na maganin ƙwayoyin TIL GC203, kuma bayan wata guda na magani da GC203, ciwon ya ragu da kashi 37.3%.
Kammalawa: Jiko na GC203yana da aminci mai karko da kuma ingantaccen tasiri ga marasa lafiya masu sake dawowa da OC waɗanda ke da iyakataccen zaɓin magani.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Nassoshi
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Lokacin Saƙo: Disamba-11-2024